Search Within

Isabelle C Riviere

  1. "Jae Park"
  2. "Meeting abstract"
  3. "Michel Sadelain"
  4. "Lymphoma"
Formats
  1. Meeting Abstract (13)
Groups
  1. Adult Leukemia (13)
  2. Center for Hematologic Malignancies (13)
  3. Department of Medicine (13)
  4. GSK Faculty (13)
  5. Hematologic Malignancies Research (13)
  6. Hematologic Malignancies, Division of (13)

More Groups

People
  1. Jae Park (13)
  2. Michel Sadelain (13)
  3. Xiuyan Wang (11)
  4. Renier Brentjens (10)
  5. Maria Palomba (9)
  6. Brigitte Senechal (8)

More People

Years
  1. 2023 (3)
  2. 2022 (2)
  3. 2021 (1)
  4. 2020 (1)
  5. 2019 (1)
  6. 2018 (1)

More Years

Publications
  1. Blood (7)
  2. Hematological Oncology (3)
  3. Clinical Lymphoma, Myeloma and Leukemia (1)
  4. Clinical Pharmacology & Therapeutics (1)
  5. Journal of Clinical Oncology (1)
Publishers
  1. American Society of Hematology (7)
  2. Wiley Blackwell (3)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Inc. (1)
  5. Nature Publishing Group (1)

Results (13)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of prophylactic anakinra to prevent neurotoxicity in patients receiving anti-CD19 CAR T-cell therapy for relapsed or refractory lymphoma: Final results from cohort 2
    Meeting Abstract

    Nath, K.; Devlin, S. M.; Sauter, C. S.; Palomba, M. L.; Shah, G. L.; Dahi, P. B.; Lin, R. J.; Scordo, M.; Perales, M. A.; Leslie, L. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Characterizing the relationship between cellular kinetics and response to support dosing recommendations for Cd19-targeted 19(T2)28z1xx cell therapy
    Meeting Abstract

    Li, J.; Singh, R.; Dey, A.; Sellner, L.; Liu, R.; Dash, A.; Park, J.; Palomba, M.; Mansilla-Soto, J.; Senechal, B.; more...
    Clinical Pharmacology & Therapeutics (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The intestinal microbiota correlates with response and toxicity after CAR T cell therapy in patients with B-cell malignancies
    Meeting Abstract

    Smith, M.; Dai, A.; Ghilardi, G.; Amelsberg, K.; Devlin, S. M.; Pajarillo, R.; Slingerland, J. B.; Beghi, S.; Herrera, P. S.; Giardina, P. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory B-cell malignancies
    Meeting Abstract

    Park, J. H.; Riviere, I.; Sikder, D. S.; Bermudez, V. P.; Senechal, B.; Wang, X.; Auchincloss, T. H.; Diamonte, C.; Halton, E.; Palomba, M. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • A phase I first-in-human clinical trial of CD19-targeted 19-28z/4-1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Batlevi, C. L.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R. R.; Bernal, Y.; Hall, M.; Pineda, J.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Meeting Abstract

    Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save